DWOAX
Price
$17.78
Change
-$0.40 (-2.20%)
Updated
Sep 6 closing price
GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
Ad is loading...

DWOAX vs GFACX

Header iconDWOAX vs GFACX Comparison
Open Charts DWOAX vs GFACXBanner chart's image
BNY Mellon Research Growth A
Price$17.78
Change-$0.40 (-2.20%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
DWOAX vs GFACX Comparison Chart
Loading...
VS
DWOAX vs. GFACX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DWOAX is a Buy and GFACX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. DWOAX (1.52B). DWOAX (0.00) and GFACX (0.00) have matching dividends . DWOAX was incepted earlier than GFACX: DWOAX (16 years) vs GFACX (24 years). GFACX (31.00) and DWOAX (30.98) have comparable annual turnover. GFACX has a lower initial minimum investment than DWOAX: GFACX (250) vs DWOAX (1000). DWOAX annual gain was more profitable for investors over the last year : 17.44 vs. GFACX (16.44). GFACX return over 5 years is better than : 38.56 vs. DWOAX (19.84).
DWOAXGFACXDWOAX / GFACX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years24 years-
Gain YTD11.12514.98274%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets1.52B270B1%
Annual Yield % from dividends0.000.00-
Returns for 1 year17.4416.44106%
Returns for 3 years-19.77-11.08178%
Returns for 5 years19.8438.5651%
Returns for 10 years27.6242.4665%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc